CalciMedica, Inc. (CALC)
$
3.11
+0.08 (2.57%)
Key metrics
Financial statements
Free cash flow per share
-0.0022
Market cap
43 Million
Price to sales ratio
716.2604
Debt to equity
0
Current ratio
5.4541
Income quality
1.5663
Average inventory
0
ROE
-2.0651
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
CalciMedica, Inc. is a clinical-stage biotechnology company dedicated to developing therapies for life-threatening inflammatory diseases where there are significant unmet needs. The company's proprietary technology focuses on the inhibition of calcium release-activated (CRAC) channels, designed to effectively modulate the immune response and protect against tissue cell injury in severe inflammatory conditions. The company achieved a revenue of $0.00 indicating its niche market focus. The EBITDA ratio is 0.00 highlighting the company's operational efficiency. Furthermore, the company recorded an operating income of -$24,204,000.00 reflecting its earnings from core operations, while the net income ratio is 0.00 reflecting the company's profitability margin. Additionally, the net total of other income and expenses is $10,504,000.00 which reflects non-core financial activities. CalciMedica’s lead product candidate, Auxora, is a proprietary intravenous-formulated CRAC channel inhibitor aimed at treating conditions such as acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. Based in La Jolla, California, CalciMedica is committed to advancing its therapeutic innovations in the biotechnology sector. The stock is affordable at $3.02 making it suitable for budget-conscious investors. With a market capitalization of $43,453,470.00 the company is classified as a small-cap player within the market. The stock has a low average trading volume of 56,206.00 indicating lower market activity, which may appeal to certain investors. As a key player in the Biotechnology industry, CalciMedica contributes significantly to the overall market landscape while driving innovation and growth within the Healthcare sector. The company's strategic focus on developing essential therapies positions it as an influential entity in addressing critical medical challenges in inflammatory diseases.
Is CalciMedica, Inc. (CALC) a good investment?
Investing in CalciMedica, Inc. (CALC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is CalciMedica, Inc. (CALC)'s stock forecast?
Analysts predict CalciMedica, Inc. stock to fluctuate between $1.42 (low) and $5.65 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is CalciMedica, Inc.'s market capitalization?
As of 2025-10-29, CalciMedica, Inc.'s market cap is $43,453,470, based on 13,972,177 outstanding shares.
How does CalciMedica, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, CalciMedica, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy CalciMedica, Inc. (CALC) stock?
To buy CalciMedica, Inc. (CALC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CALC. Place an order (Market, Limit, etc.).
What is the best time to invest in CalciMedica, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has CalciMedica, Inc. stock ever split?
CalciMedica, Inc.'s last stock split was 1:14 on 2023-03-20.
How did CalciMedica, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.22 | Growth: -84.05%.
Where can I find CalciMedica, Inc.'s investor relations reports?
Visit https://www.calcimedica.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for CalciMedica, Inc.?
You can explore historical data from here
What is the all-time high and low for CalciMedica, Inc. stock?
All-time high: $8.59 (2023-06-14) | All-time low: $1 (2023-04-03).
What are the key trends affecting CalciMedica, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
16 days ago
AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials LA JOLLA, Calif. , Oct. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, and Telperian, a clinical trial intelligence company, today announced a collaboration on the integration of Telperian's artificial intelligence (AI) engine into the analysis of clinical trial datasets from completed clinical trials of Auxora™ as well as data set simulations from publications of third-party trials.
prnewswire.com
2 months ago
LA JOLLA, Calif. , Sept. 2, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.
prnewswire.com
3 months ago
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 Productive initial meeting with the FDA on Auxora in acute pancreatitis (AP); conversations continue, with alignment on a pivotal trial anticipated around the end of 2025 Cash position expected to fund operations into mid-2026 LA JOLLA, Calif. , Aug. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2025 and provided clinical and corporate updates.
prnewswire.com
4 months ago
LA JOLLA, Calif. , July 8, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.
prnewswire.com
4 months ago
Publication includes previously announced preclinical data of Auxora™ in acute kidney injury (AKI) models as well as a post-hoc analysis of patients in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia who had AKI with respiratory failure at enrollment LA JOLLA, Calif. , June 25, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a publication in the American Journal of Nephrology (AJN) highlighting the design and rationale of the Company's Phase 2 KOURAGE trial of lead candidate Auxora™ in acute kidney injury (AKI) with respiratory failure.
prnewswire.com
5 months ago
LA JOLLA, Calif. , June 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced an upcoming symposium entitled "Auxora for the Treatment of AKI" at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting being held June 24-26 in Vicenza, Italy.
prnewswire.com
6 months ago
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif. , May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the first quarter ended March 31, 2025 and provided clinical and corporate updates.
prnewswire.com
6 months ago
LA JOLLA, Calif. , April 17, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for poster presentation at Digestive Disease Week (DDW) 2025 being held May 3-6 in San Diego, CA, and the participation of Sudarshan Hebbar, M.D.
zacks.com
7 months ago
CalciMedica Inc. (CALC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
prnewswire.com
7 months ago
LA JOLLA, Calif. , April 1, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.
See all news
